New clinical implications of anti-myelin oligodendrocyte glycoprotein antibodies in children with CNS demyelinating diseases.

Abstract

Acquired demyelinating CNS syndromes include a broad spectrum of clinical phenotypes and different entities can overlap. Therefore, differential diagnosis is still challenging. A humoral immune reaction against myelin oligodendrocyte glycoprotein (MOG) is present in a subgroup of these patients, particularly in children. Anti-MOG antibodies indicate a non-multiple sclerosis disease course. Indeed, early publications have suggested that anti-MOG antibodies argue for a monophasic course; recently an association with a high risk for recurrent non-MS disease has been shown. According new data, antibody analysis was included in a diagnostic algorithm for the diagnosis of acquired demyelinating CNS syndromes in children. Here, recent data from the implementation of anti-MOG antibodies in daily clinical practice are reviewed.

• Authors: Franziska Di Pauli, Markus Reindl, Thomas Berger
• Journal: Multiple sclerosis and related disorders (Mult Scler Relat Disord) Vol. 22 Pg. 35-37 (May 2018) ISSN: 2211-0356 [Electronic] Netherlands
• PMID: 29524760 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2018 Elsevier B.V. All rights reserved.

Chemical References

• Autoantibodies
• Biomarkers
• Myelin-Oligodendrocyte Glycoprotein

Topics

• Autoantibodies (metabolism)
• Biomarkers (metabolism)
• Child
• Demyelinating Autoimmune Diseases, CNS (metabolism)
• Humans
• Myelin-Oligodendrocyte Glycoprotein (antagonists & inhibitors)